interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride

Generic competition · all medicines · read 12 November 2026

Is there a generic of Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride, and who makes it?

Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride2 dosage-form groups in the Orange Book
0generic makers listed
  1. Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Powder, Intravenous

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

201520202025203001brand 2018data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

Solution, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Akynzeo. No generic is listed as marketed.

2020202520302035204001brand 2020data datePatent 9186357 listed to expire 18 November 2030Patent 10828297 listed to expire 17 December 2030Patent 8895586 listed to expire 23 May 2032Patent 9403772 listed to expire 23 May 2032Patent 10208073 listed to expire 23 May 2032Patent 11312698 listed to expire 23 May 2032Patent 9908907 listed to expire 23 May 2032Patent 8426450 listed to expire 23 May 2032Patent 10717721 listed to expire 23 May 2032Patent 11529362 listed to expire 2 June 2037Patent 10624911 listed to expire 2 June 2037Patent 12208109 listed to expire 2 June 2037
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 18 November 2030Patent 9186357
  • 17 December 2030Patent 10828297
  • 23 May 2032Patent 8895586
  • 23 May 2032Patent 9403772 drug substance
  • 23 May 2032Patent 10208073
  • 23 May 2032Patent 11312698 drug substance
  • 23 May 2032Patent 9908907 drug substance
  • 23 May 2032Patent 8426450 drug substance

4 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.